405 related articles for article (PubMed ID: 17891230)
1. The importance of sodium/iodide symporter (NIS) for thyroid cancer management.
Carvalho DP; Ferreira AC
Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):672-82. PubMed ID: 17891230
[TBL] [Abstract][Full Text] [Related]
2. Sodium/iodide symporter in thyroid cancer.
Mian C; Lacroix L; Bidart JM; Caillou B; Filetti S; Schlumberger M
Exp Clin Endocrinol Diabetes; 2001; 109(1):47-51. PubMed ID: 11573140
[No Abstract] [Full Text] [Related]
3. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism.
Filetti S; Bidart JM; Arturi F; Caillou B; Russo D; Schlumberger M
Eur J Endocrinol; 1999 Nov; 141(5):443-57. PubMed ID: 10576759
[TBL] [Abstract][Full Text] [Related]
4. The sodium iodide symporter: its pathophysiological and therapeutic implications.
Spitzweg C; Morris JC
Clin Endocrinol (Oxf); 2002 Nov; 57(5):559-74. PubMed ID: 12390328
[TBL] [Abstract][Full Text] [Related]
5. Expression and correlation of sodium/iodide symporter and thyroid stimulating hormone receptor in human thyroid carcinoma.
Wang ZF; Liu QJ; Liao SQ; Yang R; Ge T; He X; Tian CP; Liu W
Tumori; 2011; 97(4):540-6. PubMed ID: 21989446
[TBL] [Abstract][Full Text] [Related]
6. Association of low sodium-iodide symporter messenger ribonucleic acid expression in malignant thyroid nodules with increased intracellular protein staining.
Sodré AK; Rubio IG; Galrão AL; Knobel M; Tomimori EK; Alves VA; Kanamura CT; Buchpiguel CA; Watanabe T; Friguglietti CU; Kulcsar MA; Medeiros-Neto G; Camargo RY
J Clin Endocrinol Metab; 2008 Oct; 93(10):4141-5. PubMed ID: 18628528
[TBL] [Abstract][Full Text] [Related]
7. [The practical relevance of the sodium iodide symporter].
Spitzweg C
Z Arztl Fortbild Qualitatssich; 2004 May; 98 Suppl 5():25-32. PubMed ID: 15255310
[TBL] [Abstract][Full Text] [Related]
8. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma.
Min JJ; Chung JK; Lee YJ; Jeong JM; Lee DS; Jang JJ; Lee MC; Cho BY
Eur J Nucl Med; 2001 May; 28(5):639-45. PubMed ID: 11383871
[TBL] [Abstract][Full Text] [Related]
9. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.
Schmohl KA; Dolp P; Schug C; Knoop K; Klutz K; Schwenk N; Bartenstein P; Nelson PJ; Ogris M; Wagner E; Spitzweg C
Thyroid; 2017 Dec; 27(12):1534-1543. PubMed ID: 29032724
[TBL] [Abstract][Full Text] [Related]
10. Sodium iodide symporter: its role in nuclear medicine.
Chung JK
J Nucl Med; 2002 Sep; 43(9):1188-200. PubMed ID: 12215558
[TBL] [Abstract][Full Text] [Related]
11. Immunoanalysis indicates that the sodium iodide symporter is not overexpressed in intracellular compartments in thyroid and breast cancers.
Peyrottes I; Navarro V; Ondo-Mendez A; Marcellin D; Bellanger L; Marsault R; Lindenthal S; Ettore F; Darcourt J; Pourcher T
Eur J Endocrinol; 2009 Feb; 160(2):215-25. PubMed ID: 19029227
[TBL] [Abstract][Full Text] [Related]
12. A perspective view of sodium iodide symporter research and its clinical implications.
Riesco-Eizaguirre G; Santisteban P
Eur J Endocrinol; 2006 Oct; 155(4):495-512. PubMed ID: 16990649
[TBL] [Abstract][Full Text] [Related]
13. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.
Kogai T; Taki K; Brent GA
Endocr Relat Cancer; 2006 Sep; 13(3):797-826. PubMed ID: 16954431
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas.
Saito T; Endo T; Kawaguchi A; Ikeda M; Katoh R; Kawaoi A; Muramatsu A; Onaya T
J Clin Invest; 1998 Apr; 101(7):1296-300. PubMed ID: 9525971
[TBL] [Abstract][Full Text] [Related]
16. [The sodium-iodide symporter. Pathophysiologic, diagnostic and therapeutic significance].
Spitzweg C
Internist (Berl); 2003 Apr; 44(4):396-402, 404-8, 410-1. PubMed ID: 12914397
[TBL] [Abstract][Full Text] [Related]
17. Sodium-iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas.
Arturi F; Russo D; Giuffrida D; Schlumberger M; Filetti S
Eur J Endocrinol; 2000 Nov; 143(5):623-7. PubMed ID: 11078986
[TBL] [Abstract][Full Text] [Related]
18. Expression pattern of the pendrin and sodium/iodide symporter genes in human thyroid carcinoma cell lines and human thyroid tumors.
Arturi F; Russo D; Bidart JM; Scarpelli D; Schlumberger M; Filetti S
Eur J Endocrinol; 2001 Aug; 145(2):129-35. PubMed ID: 11454507
[TBL] [Abstract][Full Text] [Related]
19. Expression of the human sodium/iodide symporter (hNIS) in xenotransplanted human thyroid carcinoma.
Smit JW; Schröder-van der Elst JP; Karperien M; Que I; Romijn JA; van der Heide D
Exp Clin Endocrinol Diabetes; 2001; 109(1):52-5. PubMed ID: 11573141
[TBL] [Abstract][Full Text] [Related]
20. Iodide symporter gene expression in human thyroid tumors.
Arturi F; Russo D; Schlumberger M; du Villard JA; Caillou B; Vigneri P; Wicker R; Chiefari E; Suarez HG; Filetti S
J Clin Endocrinol Metab; 1998 Jul; 83(7):2493-6. PubMed ID: 9661633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
